Logo

ACON

Aclarion, Inc.

ACON

Aclarion, Inc. • NASDAQ
$6.26 ▲ 0.07% (+0.00)
Market Cap $3.64 M
52w High $3500.41
52w Low $5.55
Dividend Yield 0%
P/E 0
Volume 6.77K
Outstanding Shares 581.75K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $18.942K ▼ $1.835M ▲ $-1.706M ▼ -9.008K% ▼ $-2.93 ▼ $-1.648M ▼
Q2-2025 $19.319K ▲ $1.742M ▲ $-1.601M ▲ -8.286K% ▲ $-2.749 ▲ $-1.548M ▲
Q1-2025 $18.991K ▲ $1.487M ▼ $-2.037M ▼ -10.728K% ▲ $-9.318 ▲ $-1.982M ▼
Q4-2024 $10.232K ▼ $1.796M ▲ $-1.99M ▼ -19.445K% ▼ $-1.588K ▼ $-1.937M ▼
Q3-2024 $14.407K $1.289M $-1.366M -9.483K% $-1.321K $-1.245M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $11.341M ▼ $13.2M ▼ $699.747K ▲ $12.501M ▼
Q2-2025 $12.865M ▼ $14.755M ▼ $564.422K ▼ $14.19M ▼
Q1-2025 $14.75M ▲ $16.48M ▲ $699.032K ▼ $15.781M ▲
Q4-2024 $453.661K ▼ $2.123M ▼ $1.153M ▲ $970.057K ▼
Q3-2024 $1.312M $3.188M $678.267K $2.51M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.706M ▼ $-1.16M ▲ $-40.151K ▲ $-283.798K ▼ $-1.484M ▲ $-1.168M ▲
Q2-2025 $-1.601M ▲ $-1.866M ▲ $-44.002K ▲ $-1 ▼ $-1.91M ▼ $-1.866M ▲
Q1-2025 $-2.037M ▼ $-2.511M ▼ $-78.288K ▼ $16.886M ▲ $14.297M ▲ $-2.589M ▼
Q4-2024 $-1.99M ▼ $-899.487K ▲ $-60.717K ▲ $101.767K ▼ $-858.437K ▼ $-904.6K ▲
Q3-2024 $-1.366M $-1.056M $-103.697K $1.299M $139.411K $-1.159M

Five-Year Company Overview

Income Statement

Income Statement Aclarion appears to still be in the very early commercial stage, with essentially no recorded revenue over the past several years. The company is spending modestly on operations, which leads to ongoing losses, even if the absolute loss levels look small in the summarized data. The very extreme per‑share loss figures are largely an artifact of repeated reverse stock splits rather than a sudden collapse in business performance. Overall, this looks like a pre‑revenue, development‑focused healthcare technology company that has not yet turned its innovation into meaningful sales.

Balance Sheet

Balance Sheet The balance sheet data provided are very thin and largely rounded to zero, which suggests a very small asset base and limited financial cushion. Historically, equity has dipped into negative territory, a sign of financial stress and dependence on outside funding to keep the company operating. Multiple large reverse stock splits in back‑to‑back years point to heavy dilution and efforts to maintain listing status, which is typical of companies with strained balance sheets. In practical terms, Aclarion looks financially fragile and likely reliant on ongoing access to capital markets or strategic funding.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, even though the absolute amounts look small in the summarized figures. This pattern indicates a business that is consuming cash to fund research, development, and commercialization efforts without yet bringing in offsetting cash from customers. Capital spending appears minimal, which is consistent with a software and service‑heavy model, but it also means there is no internal cash engine yet. Overall, the company’s future depends on its ability to continue raising cash until its technology gains enough adoption to support itself.

Competitive Edge

Competitive Edge Competitively, Aclarion is positioned as a niche innovator in spinal pain diagnostics rather than a broad healthcare player. Its Nociscan platform targets a specific and hard problem—pinpointing painful spinal discs—where current tools are imperfect and often invasive. The company benefits from a first‑mover position, a growing patent portfolio, proprietary algorithms, and a solution that can plug into existing MRI workflows, all of which support some degree of competitive moat. At the same time, it is a small company operating in a conservative, evidence‑driven medical market, meaning adoption will depend heavily on clinical trial results, payer decisions, and its ability to partner with larger spine centers and imaging providers.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Aclarion’s story. Nociscan combines advanced MR spectroscopy with AI to produce an objective “pain score” for spinal discs, aiming to replace or reduce reliance on invasive and subjective diagnostic procedures. The company is investing in clinical validation, most notably through a sizable randomized trial designed to show that Nociscan‑guided decisions improve outcomes. Its patent work extends beyond low‑back pain toward infection biomarkers and broader applications, suggesting a pipeline of future use cases if the platform proves itself. The main risk is execution: scientific validation, regulatory acceptance, reimbursement, and physician adoption all need to line up for this innovation engine to translate into durable commercial success.

Summary

Aclarion is a very early‑stage, pre‑revenue healthcare technology company with promising but unproven spinal pain diagnostic technology. Financially, it appears thinly capitalized, cash‑consuming, and dependent on external funding, as reflected in minimal reported assets, repeated large reverse stock splits, and ongoing operating losses. Strategically, its strength lies in a focused, differentiated solution with patent protection, AI‑driven analytics, and compatibility with existing MRI infrastructure, all aimed at a large unmet medical need. The big swing factor is evidence: future clinical trial results, payer coverage decisions, and the pace of real‑world adoption will likely determine whether Aclarion’s innovation becomes a niche tool, a broader standard of care, or struggles to gain traction. Uncertainty is high, and the company’s path forward is tightly linked to both scientific outcomes and financing access.

NEWS

November 5, 2025 · 6:10 AM UTC

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Read more

November 5, 2025 · 6:00 AM UTC

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Read more

October 22, 2025 · 6:00 AM UTC

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Read more

October 14, 2025 · 6:13 AM UTC

Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst

Read more

October 13, 2025 · 6:04 AM UTC

Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference

Read more